Regulatory
Sep 10, 2026 · 1 min read · 65,147 views
Vera eyes full approval for Trutakna in IgAN following positive readout
N
Noah Patel
Editorial · Sep 10, 2026
Vera Therapeutics said two-year data show its recently approved drug Trutakna stabilized kidney function in patients with a chronic autoimmune disease, setting the drug up for
← Previous
More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem
Next →
HHS rolls out sweeping clinical trial reforms to counter China, RFK Jr. says
